Preferred Label : Fidaxomicin;
MeSH definition : A narrow-spectrum macrolide antibacterial agent that is used in the treatment of diarrhea
associated with CLOSTRIDIUM DIFFICILE INFECTION.;
MeSH synonym : Lipiarmycin; Tiacumicin B; Lipiarmycin A3;
MeSH hyponym : PAR101; PAR-101;
MeSH Related Number : 106008-70-2 (Lipiarmycin B3); 112396-61-9 (Lipiarmycin A4); 115178-44-4 (Lipiarmycin B4); 56645-60-4 (Fidaxomicin);
Wikipedia link : https://en.wikipedia.org/wiki/Fidaxomicin;
UNII : Z5N076G8YQ;
Origin ID : D000077732;
UMLS CUI : C0065023;
ATC code(s)
- Allowable qualifiers
- CISMeF manual mappings
- Pharmacological action(s)
- Record concept(s)
- See also inter- (CISMeF)
- Semantic type(s)
- UMLS correspondences (same concept)
- Validated automatic mappings to BTNT
A narrow-spectrum macrolide antibacterial agent that is used in the treatment of diarrhea
associated with CLOSTRIDIUM DIFFICILE INFECTION.
https://www.has-sante.fr/jcms/p_3498127/fr/dificlir-fidaxomicine-infection-a-clostridium-difficile
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
administration, oral
fidaxomicin
tablets
adult
anti-bacterial agents
time
evaluation of the transparency committee
Fidaxomicin
clostridium infections
Clostridium difficile Infections
---
https://www.has-sante.fr/jcms/p_3214276/fr/dificlir
2020
false
false
false
France
Fidaxomicin
treatment outcome
insurance, health, reimbursement
fidaxomicin
child
clostridium infections
Clostridioides difficile
guidelines for drug use
administration, oral
anti-bacterial agents
evaluation of the transparency committee
---
https://www.has-sante.fr/jcms/p_3214276/fr/dificlir-fidaxomicine-fidaxomicine
2020
false
true
false
France
French
Fidaxomicin
treatment outcome
insurance, health, reimbursement
administration, oral
fidaxomicin
anti-bacterial agents
Clostridium difficile diarrhea (disorder)
clostridium infections
diarrhea
Clostridioides difficile
evaluation of the transparency committee
---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=61973350
2013
France
summary of product characteristics
tablets
Fidaxomicin
---
http://www.has-sante.fr/portail/jcms/c_1343593/dificlir-fidaxomicine-antibiotique
http://www.has-sante.fr/portail/upload/docs/application/pdf/2012-12/dificlir_synthse_17102012_ct12235_2012-12-18_10-36-55_675.pdf
2012
France
French
antibiotic therapy
Clostridioides difficile
clostridium infections
diarrhea
administration, oral
anti-bacterial agents
adult
guidelines for drug use
evaluation of the transparency committee
treatment outcome
randomized controlled trials as topic
aminoglycosides
fidaxomicin
Fidaxomicin
---
https://www.ema.europa.eu/medicines/human/EPAR/Dificlir
2012
United Kingdom
English
French
drug evaluation
package leaflet
summary of product characteristics
syndication feed
antibiotic therapy
drug approval
treatment outcome
aminoglycosides
aminoglycosides
administration, oral
adult
anti-bacterial agents
anti-bacterial agents
Clostridioides difficile
enterocolitis, pseudomembranous
drug interactions
pregnancy
breast feeding
DNA-Directed RNA polymerases
fidaxomicin
Fidaxomicin
Fidaxomicin
---
Summary Basis of Decision (SBD) for Dificid
Fidaxomicin, 200 mg, Tablet, Oral
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailOne.php?lang=fr&linkID=SBD00043
2012
false
Canada
French
English
antibiotic therapy
drug information
Product containing precisely fidaxomicin 200 milligram/1 each conventional release
oral tablet (clinical drug)
administration, oral
anti-bacterial agents
anti-bacterial agents
adult
Clostridioides difficile
treatment outcome
clinical trials, phase iii as topic
clostridium infections
canada
drug approval
drug evaluation, preclinical
drug evaluation
risk assessment
aminoglycosides
aminoglycosides
fidaxomicin
Fidaxomicin
Fidaxomicin
---
http://www.has-sante.fr/portail/jcms/c_1332053/dificlir
http://www.has-sante.fr/portail/upload/docs/application/pdf/2012-11/dificlir_17102012_avis_ct_12235.pdf
2012
France
French
antibiotic therapy
administration, oral
insurance, health, reimbursement
anti-bacterial agents
anti-bacterial agents
Clostridioides difficile
clostridium infections
adult
enterocolitis, pseudomembranous
aged
treatment outcome
clinical trials, phase iii as topic
risk management
evaluation of the transparency committee
aminoglycosides
aminoglycosides
fidaxomicin
Fidaxomicin
Fidaxomicin
---
